Transcode Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Transcode Therapeutics R&D Spending Growth & History (RNAZ)
Transcode Therapeutics's r&d spending was $13.4M for fiscal 2025.
View full Transcode Therapeutics company overviewTranscode Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $13.4M | $3.7M | +38.28% |
| 2024 | 2024-12-31 | $9.7M | −$2.6M | −20.85% |
| 2023 | 2023-12-31 | $12.3M | $2.0M | +19.85% |
| 2022 | 2022-12-31 | $10.2M | $7.5M | +271.55% |
| 2021 | 2021-12-31 | $2.8M | $2.5M | +868.14% |
| 2020 | 2020-12-31 | $284,459 | — | — |
Transcode Therapeutics quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.7M | $1.1M | +43.96% |
| Q1 2026 | 2026-03-31 | $5.1M | $2.9M | +130.09% |
| Q4 2025 | 2025-12-31 | $5.5M | $1.8M | +50.49% |
| Q3 2025 | 2025-09-30 | $3.2M | $1.9M | +157.54% |
| Q2 2025 | 2025-06-30 | $2.6M | −$515,595 | −16.73% |
| Q1 2025 | 2025-03-31 | $2.2M | $460,507 | +26.18% |
| Q4 2024 | 2024-12-31 | $3.6M | $274,749 | +8.17% |
| Q3 2024 | 2024-09-30 | $1.2M | −$2.1M | −63.28% |
| Q2 2024 | 2024-06-30 | $3.1M | $115,667 | +3.90% |
| Q1 2024 | 2024-03-31 | $1.8M | −$832,330 | −32.12% |
| Q4 2023 | 2023-12-31 | $3.4M | $676,888 | +25.19% |
| Q3 2023 | 2023-09-30 | $3.3M | $298,620 | +9.81% |
| Q2 2023 | 2023-06-30 | $3.0M | $345,882 | +13.20% |
| Q1 2023 | 2023-03-31 | $2.6M | $709,774 | +37.72% |
| Q4 2022 | 2022-12-31 | $2.7M | $1.4M | +109.00% |
| Q3 2022 | 2022-09-30 | $3.0M | $2.1M | +206.56% |
| Q2 2022 | 2022-06-30 | $2.6M | $2.4M | +1137.31% |
| Q1 2022 | 2022-03-31 | $1.9M | $1.6M | +613.37% |
| Q4 2021 | 2021-12-31 | $1.3M | — | — |
| Q3 2021 | 2021-09-30 | $992,946 | $939,010 | +1740.97% |
| Q2 2021 | 2021-06-30 | $211,752 | $136,752 | +182.34% |
| Q1 2021 | 2021-03-31 | $263,759 | — | — |
| Q3 2020 | 2020-09-30 | $53,936 | — | — |
| Q2 2020 | 2020-06-30 | $75,000 | — | — |
Transcode Therapeutics r&d spending trends
Over the last five fiscal years, Transcode Therapeutics's r&d spending increased from $284,459 to $13.4M, a change of $13.1M. The latest reported quarter, Q2 2026, shows $3.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Transcode Therapeutics source filings ↗